Product Images Lenalidomide

The text describes a clinical study comparing the efficacy of Lenalidomide versus placebo in terms of progression-free survival. It provides data on hazard ratio, confidence intervals, and median survival times for each group. Additionally, it shows the number of subjects at risk and the percentage of progression-free survival events in each group. The study results suggest that Lenalidomide may be associated with improved progression-free survival compared to placebo.*

This is a comparison of Lenalidomide versus placebo in terms of progression-free survival. The hazard ratio was 0.53 (95% CI: 0.44, 0.64) indicating a lower risk of progression with Lenalidomide. The median survival was also longer with Lenalidomide (46.3 months, 95% CI: 40.1, 56) compared to placebo (23.8 months, 95% CI: 21.0, 27.3). The number of subjects at risk and PFS events are also provided for both groups.*

This text provides information on the proportion of subjects at different points during a study, alongside statistics related to the survival analysis of the participants receiving Lenalidomide/Dex treatment for a specified duration of time. The hazard ratio (HR) and confidence interval (CI) values are indicated, along with the results of the log-rank test showing statistical significance. The number of subjects at various percentage levels (100%, 75%, 25%) is also presented.*

This data likely presents the results of a study comparing the proportion of subjects who experienced progression by a certain time point between two treatments, Lenalidomide/Dex and Placebo/Dex. The Hazard Ratio (HR) with 95% confidence interval is shown as 0.324 (0.240-0.438), indicating a significant difference between the two groups. Additionally, the Log Rank p-value is less than 0.001, further supporting the statistical significance of the findings. The chart also includes a visual representation of the time to progression in months for both groups.*